Drug Drug Interaction Study for EYP001 With Entecavir

Summary

This is a Phase 1, single-center, open-label, three subsequent dosing periods study to evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD), safety, and tolerability of a single dose of EYP100a combined with ETV in healthy men and women dosed in the morning under fasted conditions.

Timeline

Start

2018-02-12

Primary completion

2018-06-20

Completion

2018-07-20

Drugs

Indications